C-8901 Cabozantinib, Free Base, >99%

Synonyms : [BMS-907351] [Cabo-S-Malate] [XL-184]

Related Terms : [Cabometyx] [Cometriq]

  • Size
  • US $
  • £
  • ¥
  • 50 mg
  • 53
  • 48
  • 40
  • 8,400
  • Add to Cart
  • Out of stock
  • 100 mg
  • 66
  • 60
  • 50
  • 10,400
  • Add to Cart
  • Out of stock
  • 200 mg
  • 105
  • 96
  • 80
  • 16,600
  • Add to Cart
  • Out of stock
  • 500 mg
  • 223
  • 204
  • 171
  • 35,300
  • Add to Cart
  • Out of stock
  • 1 g
  • 395
  • 362
  • 304
  • 62,400
  • Add to Cart
  • Out of stock
  • 2 g
  • 634
  • 582
  • 488
  • 100,200
  • Add to Cart
  • Out of stock
  • 5 g
  • 1,125
  • 1,032
  • 867
  • 177,800
  • Add to Cart
  • Out of stock
  • 10 g
  • 1,760
  • 1,615
  • 1,356
  • 278,200
  • Add to Cart
  • Out of stock

Note: Our Euro, Pound, and Yen prices are revised regularly to account for currency exchange rate fluctuations.

To receive a Formal Quotation for catalog sizes of this product and/or any other products, please add them to your shopping cart and click on the “REQUEST A QUOTATION” box.
Click Here to Request a Quotation for Larger Quantities Free Shipping and Handling to the U.S. and 32 Other Countries
  • M.W. 501.51
  • C28H24FN3O5
  • [849217-68-1]

Solubility: Soluble in DMSO at 50 mg/mL; very poorly soluble in ethanol; very poorly soluble in water; maximum solubility in plain water is estimated to be about 2-4 µM; buffers, serum, or other additives may increase or decrease the aqueous solubility.

Select Lot Number to view Certificate of Analysis

View the SDS for this product

  • July 27, 2023:  we expect our next  lot of  C-8901 Cabozantinib, Free Base to be ready to ship during the week of August 14, 2023 or sooner.
  • Cabozantinib, also known as XL184, is an orally bioavailable novel tysosine kinase inhibitor of c-MET and VEGF receptor 2 (VEGFR2). It inhibited MET and VEGFR2 with IC50 values of 1.3 nM and 35 pM, respectively. It also inhibited MET-activating kinase domain mutations Y1248H, D1246N, or K1262R with IC50 values of 3.8, 11.8, and 14.6 nM, respectively. It strongly inhibited several kinases that are implicated in tumor pathobiology including KIT, RET, AXL, TIE2, and FLT3 with IC50 values of 4.6, 5.2, 7, 14.3, and 11.3 nM, respectively. In cellular assays, cabozantinib inhibited phosphorylation of MET, VEGFR2, KIT, FLT3, and AXL with IC50 values of 7.8, 1.9, 5.0, 7.5, and 42 [micro]M, respectively. Cabozantinib inhibited tumor angiogenesis, tumor growth and metastasis in cancers with dysregulated MET and VEGFR signaling. Yakes F.M., et al "Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth." Mol. Cancer Ther. 10: 2298-2308 (2011).
  • This research compound is the free base form of cabozantinib. We also offer the s-malate salt form of cabozantinib: Cat. No. C-8999, Cabozantinib, S-Malate Salt.
  • This cabozantinib product is the free base, whose CAS number is given above. The CAS number of the s-Malate salt form is 1140909-48-3.
  • Treatment of RIP-Tag2 mice with cabozantinib eliminated approximately 80% of the vasculature of spontaneous pancreatic islet tumors over 7 days, reduced pericytes and empty basement membrane sleeves, resulted in widespread intratumoral hypoxia and tumor cell apoptosis, and delayed regrowth of the tumor vasculature after drug withdrawal. Importantly, it also inhibited invasiveness of primary tumors and reduced metastasis. You W.K., et al. "VEGF and c-Met blockade amplify angiogenesis inhibition in pancreatic islet cancer." Cancer Res. 71: 4758-4768 (2011).
  • Cabozantinib is active in patients with medullary thyroid cancer and has an acceptable safety profile. Kurzrock R., et al. "Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer." J. Clin. Oncol. 29: 2660-2666 (2011).
  • Cabozantinib 40 mg daily was associated with a high rate of bone scan response and better tolerability in patients with metastatic castration-resistant prostate cancer when compared with previously reported results for cabozantinib 100 mg daily. Lee R.J., et al. "A dose-ranging study of cabozantinib in men with castration-resistant prostate cancer and bone metastases." Clin Cancer Res. 19: 3088-3094 (2013).
  • Cabozantinib demonstrated activity in patients with metastatic melanoma in a phase 2 randomized discontinuation trial. Gordon M.S. etal. "Activity of Cabozantinib (XL184) in Metastatic Melanoma: Results From a Phase 2 Randomized Discontinuation Trial (RDT)." http://www.exelixis.com/sites/default/files/2012-06-02_Gordon%20Melanoma_ASCO%202012%20FINAL_poster_8531.pdf
  • Cabozantinib was active in patients with metastatic non-small cell lung cancer (NSCLC) in a phase 2 randomized discontinuation trial. Hellerstedt B.A. et al. "Activity of Cabozantinib (XL184) in Metastatic NSCLC: Results From a Phase 2 Randomized Discontinuation Trial (RDT)." http://www.exelixis.com/sites/default/files/2012-06-05_Hellerstedt%20NSCLC_ASCO%202012_FINAL_poster_7514.pdf
  • Cabozantinib (as the s-malate salt) is the active ingredient in the drug product sold under the trade name Cabometyx® and Cometriq®. This drug is currently approved in at least one country for use in patients with progressive, metastatic medullary thyroid cancer.  It is currently undergoing clinical trials for the treatment of prostate, ovarian, brain, melanoma, breast, non-small cell lung, pancreatic, hepatocellular and kidney cancers.  NOTE: THE CABOZANTINIB SOLD BY LC LABORATORIES FOR RESEARCH IS NOT CABOMETYX® or COMETRIQ®, AND IS NOT FOR HUMAN USE.
  • Sold for laboratory or manufacturing purposes only; not for human, veterinary, food, or household use
  • This product is offered for R&D use in accordance with (i) 35 USC 271(e)+A13(1) in the U.S.; (ii) Section 69.1 of Japanese Patent Law in Japan; (iii) Section 11, No. 2 of the German Patent Act of 1981 in Germany; (iv) Section 60, Paragraph 5b of the U.K. Patents Act of 1977 in the U.K.; (v) Sections 55.2(1) and 55.2(6) and other common law exemptions of Canadian patent law; (vi) Section 68B of the Patents Act of 1953 in New Zealand together with the amendment of same by the Statutes Amendment Bill of 2002; (vii) such related legislation and/or case law as may be or become applicable in the aforementioned countries; and (viii) such similar laws and rules as may apply in various other countries.
  • Not available in some countries; not available to some institutions; not available for some uses.